Independent assessment of ALC thresholds currently in use to predict motor/neurocognitive toxicities (MNTs) after treatment with ciltacabtagene autoleucel
Yein Jeon(University of Washington), Jordan Gauthier(Seattle Cancer Care Alliance), Erik L. Kimble(University of Washington), Danai Dima(Fred Hutch Cancer Center), Andrew J. Cowan(University of Washington Medical Center), Qian Wu(Cancer Research Center), Andrew J. Portuguese(University of Washington), Christy Khouderchah(University of Washington), Alexandre V. Hirayama(University of Washington), Rahul Banerjee(University of Washington), Meredith Durbin, Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Emily C. Liang(Fred Hutch Cancer Center), Xiancheng Wu(Fred Hutch Cancer Center), Jennifer Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Madhav V. Dhodapkar(Yale Cancer Center), Mazyar Shadman(University of Washington)
Cited by 0
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
|Nature Medicine|1999|1.1k
Global Burden of Multiple Myeloma
|JAMA Oncology|2018|631